Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ bone marrow-derived stem cells (AskBio)
- Development stage
- Unknown
- Lead developer
- Asklepios proresearch
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary, Intramyocardial
01
Overview
Autologous CD133+ bone marrow-derived stem cells are an investigational cell therapy developed for the treatment of chronic ischemic cardiomyopathy. The therapy involves harvesting a patient's own bone marrow and enriching it for CD133-positive cells, which represent a population of primitive hematopoietic and endothelial progenitor cells with high regenerative potential. These cells are intended to be delivered to the ischemic myocardium—either via intracoronary infusion or direct intramyocardial injection—to stimulate neovascularization and improve cardiac function. The therapeutic effect is primarily mediated through paracrine signaling, where the cells secrete various growth factors and cytokines that promote angiogenesis, reduce apoptosis, and potentially facilitate myocardial repair. The AlsterMACS pilot study, conducted by Asklepios proresearch, specifically compared these two delivery routes to determine the most effective method for improving left ventricular ejection fraction in patients with chronic heart failure.
- Other names
- CD133+ bone marrow stem cellsautologous CD133+ cellsAlsterMACS CD133+ stem cells
Beyond the preview
Go deeper on autologous CD133+ bone marrow-derived stem cells (AskBio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ bone marrow-derived stem cells (AskBio).